CRISPR Therapeutics to Present at the 16th Annual Needham Healthcare Conference
BASEL, Switzerland and CAMBRIDGE, Mass., March 30, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into transformative medicines, today announced that Dr. Sam Kulkarni, Chief Business Officer of CRISPR Therapeutics, will present at the 16th Annual Needham Healthcare Conference on Wednesday, April 5th at the Westin Grand Central Hotel, New York, NY.
Event: 16th Annual Needham Healthcare Conference
Date: Wednesday, April 5th
Time: 12:50-1:30 PM ET
A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors & Media section of the Company's website at www.crisprtx.com.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR / Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR/Cas9 patent estate for human therapeutic use was licensed from the company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics is headquartered in Basel, Switzerland with its R&D operations based in Cambridge, Massachusetts. For more information, please visit www.crisprtx.com.
MEDIA CONTACTS: Jennifer Paganelli WCG for CRISPR 347-658-8290 firstname.lastname@example.org INVESTOR CONTACT: Chris BrinzeyWestwicke Partners for CRISPR 339-970-2843 email@example.com
You are now leaving the CRISPR Therapeutics website.
CRISPR Therapeutics is not responsible for the content or availability of third-party sites.